Skip to main
ARAY

Accuray (ARAY) Stock Forecast & Price Target

Accuray (ARAY) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 0%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Accuray is a radiation oncology company with a strong focus on precision and accuracy in treating cancer and tumors using its unique CyberKnife technology. However, the company's financial performance has been impacted by geopolitical uncertainty and macroeconomic headwinds, causing it to trade at a discount to its peers. While management has implemented a transformation plan to improve profitability, the company's ability to achieve consistent revenue growth remains a key concern. As a result, BTIG has maintained a Neutral rating on the stock and has reduced its price target to $2.

Bears say

Accuray is facing multiple challenges, including geopolitical uncertainty in the Middle East, declining revenues due to lower product and service orders, and difficulties in commercial execution and profitability. These challenges have led us to revise our outlook to negative and to reduce our forecasted revenues, gross orders, and EBITDA for both the current year and the outyears. We also see risks from geopolitical tensions, tariffs, supply chain challenges, and potential delays in product development.

Accuray (ARAY) has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 0% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Accuray and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Accuray (ARAY) Forecast

Analysts have given Accuray (ARAY) a Buy based on their latest research and market trends.

According to 2 analysts, Accuray (ARAY) has a Buy consensus rating as of Jun 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $1.18, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $1.18, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Accuray (ARAY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.